Gilead Sciences, Inc.
Capitalisation boursière
$193.5B
Rang mondial
#81
Sommet historique
$195.1B
2026-10-16
Croissance totale
+0%
depuis 2026
Market Cap Context
- Larger than 78% of the 367 companies we track (globally).
- Equivalent to 0.6% of United States's GDP (2025 data).
- Just above: #80 Walt Disney ($194.3B)
- Just below: #82 Reliance Industries ($192.4B)
- Best year: 1995 (+237%). Worst year: 2016 (-28%).
Gilead Sciences, Inc. Financial Breakdown (FY 2025)
Source: Yahoo Finance — GILD annual filings (2025) →$29.4B revenue · $11.7B operating income · $8.5B net income
- ●Operating margin: 39.7% on $29.4B in revenue.
- ●R&D is 19.7% of revenue ($5.8B).
- ●Net income margin: 28.9% — $8.5B in profit.
- ●Free cash flow: $9.5B (32.1% of revenue).
Cost / Operating Expenses
Total operating expenses $17.7B
Total
$17.7B
Capital Expenditures
$0.6B
This fiscal year (near-total AI infrastructure buildout)
Free Cash Flow
$9.5B
Trailing twelve months
Figures rounded from the annual SEC filing. Unaudited. For informational purposes only, not investment advice.
À propos de Gilead Sciences, Inc.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
Historique de la capitalisation boursière de Gilead Sciences, Inc. (2026–2026)
Gilead Sciences, Inc. vs Sector Peers by Market Cap
Comparer Gilead Sciences, Inc.
Historique du classement
| Année | Capitalisation boursière | Rang | Variation sur un an |
|---|---|---|---|
| 2026 | $193.5B | #81(↑27) | +28.5% |
| 2025 | $150.5B | #108(↑14) | +36.8% |
| 2024 | $110.0B | #122 | +18.8% |
| 2023 | $92.6B | #122(↓21) | -2.1% |
| 2022 | $94.6B | #101(↑27) | +23.9% |
| 2021 | $76.4B | #128(↑19) | +30.1% |
| 2020 | $58.7B | #147(↓39) | -6.9% |
| 2019 | $63.0B | #108(↓21) | +7.8% |
| 2018 | $58.5B | #87(↓7) | -10.1% |
| 2017 | $65.0B | #80(↓17) | +2.9% |
| 2016 | $63.2B | #63(↓27) | -27.7% |
| 2015 | $87.4B | #36(↑5) | +8.2% |
| 2014 | $80.8B | #41(↑6) | +25.5% |
| 2013 | $64.4B | #47(↑34) | +104.5% |
| 2012 | $31.5B | #81(↑39) | +79.5% |
| 2011 | $17.6B | #120(↑23) | +12.9% |
| 2010 | $15.5B | #143(↓33) | -16.2% |
| 2009 | $18.6B | #110(↓48) | -15.4% |
| 2008 | $21.9B | #62(↑50) | +11.1% |
| 2007 | $19.7B | #112(↑29) | +41.7% |
| 2006 | $13.9B | #141(↓3) | +23.5% |
| 2005 | $11.3B | #138(↑21) | +50.2% |
| 2004 | $7.5B | #159(↓4) | +20.1% |
| 2003 | $6.2B | #155(↑13) | +71.4% |
| 2002 | $3.6B | #168(↑20) | +3.5% |
| 2001 | $3.5B | #188(↑5) | +58.5% |
| 2000 | $2.2B | #193(↓23) | +53.2% |
| 1999 | $1.5B | #170(↓9) | +31.8% |
| 1998 | $1.1B | #161(↓5) | +7.4% |
| 1997 | $1.0B | #156 | +53.0% |
| 1996 | $670.1M | #156(↓18) | -21.9% |
| 1995 | $857.7M | #138(↓4) | +236.8% |
| 1994 | $254.6M | #134 |
Autres entreprises du secteur Santé
FAQ
What is Gilead Sciences, Inc.'s market cap?
Gilead Sciences, Inc. (GILD) has a market capitalization of $193.5B, making it the #81 largest company in the world by market cap.
What was Gilead Sciences, Inc.'s highest market cap?
Gilead Sciences, Inc.'s all-time high market cap was $195.1B, reached in 2026-10-16. Its highest rank was #81 in 2026.
What sector is Gilead Sciences, Inc. in?
Gilead Sciences, Inc. is in the Healthcare sector, specifically the Drug Manufacturers - General industry. It is based in United States.
How has Gilead Sciences, Inc.'s market cap changed over time?
Gilead Sciences, Inc. has been tracked since 2026. Its market cap has grown by 0% from $193.5B in 2026 to $193.5B today.